[go: up one dir, main page]

Ulusoy et al., 2010 - Google Patents

Viral vector-mediated overexpression of α-synuclein as a progressive model of Parkinson's disease

Ulusoy et al., 2010

View PDF
Document ID
969424743991994261
Author
Ulusoy A
Decressac M
Kirik D
Björklund A
Publication year
Publication venue
Progress in brain research

External Links

Snippet

The discovery of the role of α-synuclein in the pathogenesis of Parkinson's disease (PD) has opened new possibilities for the development of more authentic models of Parkinson's disease. Recombinant adeno-associated virus (AAV) and lentivirus (LV) vectors are efficient …
Continue reading at www.neurobiology.lu.se (PDF) (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA Viruses
    • C12N2750/00011—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA Viruses ssDNA Viruses
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0623—Stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes

Similar Documents

Publication Publication Date Title
Ulusoy et al. Viral vector-mediated overexpression of α-synuclein as a progressive model of Parkinson’s disease
US11939355B2 (en) Variant adeno-associated viruses and methods of using
US20230203531A1 (en) Tissue selective transgene expression
Arrant et al. Progranulin gene therapy improves lysosomal dysfunction and microglial pathology associated with frontotemporal dementia and neuronal ceroid lipofuscinosis
Volpicelli‐Daley et al. How can rAAV‐α‐synuclein and the fibril α‐synuclein models advance our understanding of Parkinson's disease?
JP6317440B2 (en) Methods and compositions for inhibiting oxidative stress
KR20200039617A (en) Adeno-associated virus capsid variants and methods of use thereof
US20030118552A1 (en) Targeted retrograde gene delivery for neuronal protection
WO2019068854A1 (en) Gene therapy of neurodegenerative diseases using aav vectors
Korecka et al. Repulsive guidance molecule a (RGMa) induces neuropathological and behavioral changes that closely resemble Parkinson's disease
Yasuda et al. Effects of UCH‐L1 on α‐synuclein over‐expression mouse model of Parkinson’s disease
US20230365963A1 (en) Methods for treating neurological disease
CN110121356A (en) The method and carrier for treating CNS disease
Sizemore et al. Viral vector-based tools advance knowledge of basal ganglia anatomy and physiology
IL297404A (en) Codon optimized gla genes and uses thereof
Schober et al. Recombinant adeno-associated virus serotype 6 (rAAV6) potently and preferentially transduces rat astrocytes in vitro and in vivo
AU2024205206A1 (en) Method for managing pain
Okada et al. Adeno-associated virus vectors for gene transfer to the brain
WO2017201425A1 (en) Anabolic enhancers for ameliorating neurodegeneration
CA3077105C (en) Recombinant dgkk gene for fragile x syndrome gene therapy
Surdyka et al. Selective transduction of cerebellar Purkinje and granule neurons using delivery of AAV-PHP. eB and AAVrh10 vectors at axonal terminal locations
Williams et al. The assessment of adeno‐associated vectors as potential intrinsic treatments for brainstem axon regeneration
CN116723868A (en) Methods of treating neurological disorders
Cao et al. Virally mediated knock-down of NR2 subunits ipsilateral to the deprived eye blocks ocular dominance plasticity
Aimiuwu Modeling Gene Therapy for Intractable Developmental and Epileptic Encephalopathy